The 4 most recent market catalysts affecting $ALT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 55
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Evercore ISI Group's analyst Liisa Bayko maintained an 'Outperform' rating on Altimmune (ALT) but reduced the price target from $18 to $17. This action signals that while the analy…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 92
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Altimmune announced its Q2 earnings, reporting a loss of $(0.12) per share, which was better than the analyst consensus estimate of $(0.15). This 20% beat, coupled with a 55.56% im…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune reported highly encouraging Phase 2 trial results for pemvidutide in treating alcohol use disorder, showing statistically significant reductions in heavy drinking days an…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 95
Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
Altimmune (ALT) announced highly positive topline results from its Phase 2 RECLAIM trial for pemvidutide in alcohol use disorder (AUD). The drug met its primary endpoint of reducin…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.